Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | GBA1 | P04062 | 6/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189833 | 1.00 | FUCA1 (0.47) | FUCA1GAAGBA1ABCB1TACR3 | |
| SCHEMBL17542008 | 0.90 | ABCB1 (0.43) | FUCA1GAAGBA1ABCB1TACR3 | |
| SCHEMBL28879326 | 0.90 | ABCB1 (0.43) | FUCA1GAAGBA1ABCB1TACR3 | |
| SCHEMBL17610289 | 0.84 | ABCB1 (0.43) | FUCA1ABCB1TACR3S1PR1S1PR5 | |
| SCHEMBL1189349 | 0.84 | ABCB1 (0.43) | FUCA1ABCB1TACR3S1PR1S1PR5 | |
| SCHEMBL14692745 | 0.84 | ABCB1 (0.40) | FUCA1GAAGBA1ABCB1TACR3 | |
| SCHEMBL17801553 | 0.81 | PSEN1 (0.40) | ABCB1 | |
| SCHEMBL17542526 | 0.79 | ALDH1A1 (0.37) | MEN1KMT2A | |
| SCHEMBL18577142 | 0.79 | TSHR (0.42) | GAAS1PR5 | |
| SCHEMBL17542235 | 0.79 | TACR3 (0.43) | ABCB1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | FUCA1 991/4885GAA 1321/4885GBA1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.